Botta, Cirino
 Distribuzione geografica
Continente #
NA - Nord America 2.113
EU - Europa 925
AS - Asia 87
SA - Sud America 9
AF - Africa 7
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.151
Nazione #
US - Stati Uniti d'America 2.071
IT - Italia 518
GB - Regno Unito 110
IE - Irlanda 60
DE - Germania 51
CA - Canada 40
RU - Federazione Russa 40
BE - Belgio 27
CN - Cina 24
EE - Estonia 19
HK - Hong Kong 18
FR - Francia 14
FI - Finlandia 13
UA - Ucraina 13
CH - Svizzera 10
IN - India 9
SE - Svezia 9
JP - Giappone 7
UZ - Uzbekistan 6
ES - Italia 5
NL - Olanda 5
RO - Romania 5
TR - Turchia 5
AT - Austria 4
KR - Corea 4
NZ - Nuova Zelanda 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
AU - Australia 3
CL - Cile 3
CZ - Repubblica Ceca 3
GR - Grecia 3
HU - Ungheria 3
SG - Singapore 3
BR - Brasile 2
EG - Egitto 2
ET - Etiopia 2
LK - Sri Lanka 2
NO - Norvegia 2
RS - Serbia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
HR - Croazia 1
IR - Iran 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
PL - Polonia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 3.151
Città #
Chandler 375
Fairfield 276
Ashburn 244
Medford 122
Wilmington 115
Altamura 114
Princeton 79
Lawrence 77
Cambridge 76
Palermo 71
Houston 64
San Diego 64
Dublin 57
Woodbridge 45
London 41
Seattle 33
Toronto 33
Ann Arbor 29
Brussels 27
Milan 19
Rome 19
Tallinn 19
Beijing 14
Kilburn 12
New York 12
Saint Petersburg 11
Catania 10
Ludwigshafen am Rhein 10
Naples 10
Noto 9
San Paolo di Civitate 9
Abbiategrasso 8
Chicago 8
Florence 8
Hounslow 8
Edinburgh 7
Helsinki 7
Lappeenranta 6
Tokyo 6
Turin 6
Bari 5
Boydton 5
Castrovillari 5
Central 5
Central District 5
Norwalk 5
Redwood City 5
Sciara 5
Vicenza 5
Auckland 4
Bremen 4
Caserta 4
Catanzaro 4
Chiswick 4
Clearwater 4
Moscow 4
Novara 4
Prescot 4
Romainville 4
Apo 3
Aversa 3
Cagliari 3
Cavallino 3
Cingoli 3
Corropoli 3
Dallas 3
Hong Kong 3
Islington 3
Kerken 3
Kiev 3
Kowloon 3
Melilli 3
Mendicino 3
Mountain View 3
Ponzano Veneto 3
Shanghai 3
Stockholm 3
Verona 3
Vienna 3
Wandsworth 3
Washington 3
Addis Ababa 2
Agrigento 2
Alcamo 2
Amsterdam 2
Andover 2
Ankara 2
Beograd 2
Bologna 2
Boston 2
Brooklyn 2
Budapest 2
Cairo 2
Caldogno 2
Caltanissetta 2
Castrolibero 2
Cedar Knolls 2
Cetraro 2
Clusone 2
Colombo 2
Totale 2.349
Nome #
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation 117
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 99
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing 80
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 67
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 65
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 64
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 58
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) 58
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma 51
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis 51
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it? 51
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 51
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma 50
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 50
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 50
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 49
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm 48
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 48
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report 47
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 47
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates 47
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 47
miR-22 suppresses DNA ligase III addiction in multiple myeloma 46
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes 46
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 45
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 44
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma 44
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 44
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 44
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 44
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer 43
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 43
Mouse models of multiple myeloma: Technologic platforms and perspectives 42
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma 42
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 42
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 42
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 41
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 41
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells 41
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 41
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities 41
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 40
Could PD-1/PDL1 immune checkpoints be linked to HLA signature? 40
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 39
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 39
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response 39
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 39
Immunologic characterization of COVID-19 patients with hematological cancer 38
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 38
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 38
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 38
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant 38
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab 37
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 37
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients 37
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 37
Immunotherapy of colorectal cancer: New perspectives after a long path 37
Myeloid derived suppressor cells in multiple myeloma: Preclinical research and translational opportunities 36
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma 36
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 36
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation 36
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells 36
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma 35
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 35
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 35
Immunomodulatory activity of microRNAs: Potential implications for multiple myeloma treatment 34
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 34
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse 34
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 34
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma 33
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients 32
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 32
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 32
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer 31
Immunologic microenvironment and personalized treatment in multiple myeloma 31
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials 30
MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 30
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies 29
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients 27
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination 27
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma 26
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice 24
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 24
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma 23
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients 23
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 21
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy 21
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma 21
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials 20
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma 14
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 13
Multiple Myeloma in 2023 Ways: From Trials to Real Life 13
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance 10
Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing 10
null 3
Totale 3.743
Categoria #
all - tutte 25.143
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.143


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021774 0 0 0 0 0 0 0 0 9 4 19 742
2021/2022912 56 131 28 27 23 76 44 43 100 153 61 170
2022/20231.407 109 247 94 112 146 182 24 142 157 21 127 46
2023/2024650 48 118 64 123 74 75 69 56 23 0 0 0
Totale 3.743